Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Mvasi (bevacizumab-awwb) is a biosimilar to the anti-VEGF antibody Avastin (bevacizumab), which binds to and inhibits VEGF, resulting in decreased tumor growth and angiogenesis (PMID: 29743182). Mvasi (bevacizumab-awwb) is FDA approved for use in combination with chemotherapy in colorectal cancer, in combination with carboplatin and paclitaxel in non-squamous non-small cell lung cancer, in glioblastoma, in combination with interferon-alfa in renal cell carcinoma, and in combination with paclitaxel and cisplatin or topotecan in cervical cancer (FDA.gov).
|DrugClasses||VEGF Antibody 11|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Bevacizumab-awwb + Carboplatin + Paclitaxel||Bevacizumab-awwb Carboplatin Paclitaxel||1||0|